22157.jpg
Global Oral Thin Film Drugs Markets, 2022-2030 with 2021 as the Base Year - Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts
February 10, 2023 06:08 ET | Research and Markets
Dublin, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The "Oral Thin Film Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
22157.jpg
Global Oral Thin Films Market Report to 2031 - Featuring ZIM Laboratories, NAL Pharma, Cure Pharmaceutical and IntelGenx Among Others
September 19, 2022 06:23 ET | Research and Markets
Dublin, Sept. 19, 2022 (GLOBE NEWSWIRE) -- The "Oral Thin Films Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers...
22157.jpg
Global Novel Drug Delivery Systems (NDDS) Market Outlook, 2026 - Microfluidics Mediated NDDS Set to Make Gains
February 07, 2022 06:58 ET | Research and Markets
Dublin, Feb. 07, 2022 (GLOBE NEWSWIRE) -- The "Novel Drug Delivery Systems (NDDS) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Novel...
22157.jpg
Worldwide Oral Thin Films Industry to 2026 - The Sublingual Film Segment Holds a Significant Share of the Market
December 29, 2021 08:53 ET | Research and Markets
Dublin, Dec. 29, 2021 (GLOBE NEWSWIRE) -- The "Oral Thin Films Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering. ...
CURE Logo.png
CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel
July 15, 2020 08:00 ET | CURE Pharmaceutical Holding Corp.
OXNARD, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that its 25mg cannabidiol (CBD) oral thin film...
CURE Logo.png
CURE Pharmaceutical [OTCQB:CURR] Secures Patent on High Loading of Active Ingredient in Oral Thin Films
July 24, 2019 07:25 ET | Cure Pharmaceutical Holding Corp.
OXNARD, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No....
CURE Logo.png
CURE Pharmaceutical [OTCQB:CURR] Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients
July 16, 2019 07:25 ET | Cure Pharmaceutical Holding Corp.
OXNARD, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No....
CURE Logo.png
CURE Pharmaceutical [OTCQB:CURR] and Canopy Growth to Produce CBD Oral Thin Films
June 19, 2019 07:25 ET | Cure Pharmaceutical Holding Corp.
OXNARD, Calif. , June 19, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth...
CURE Logo.png
CURE Pharmaceutical (OTCQB:CURR) Closes Acquisition Of Privately-Held Chemistry Holdings Inc.
May 14, 2019 09:25 ET | Cure Pharmaceutical Holding Corp.
OXNARD, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has closed on the previously...
CURE Logo.png
Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA
May 02, 2019 07:25 ET | Cure Pharmaceutical Holding Corp.
CHICAGO, May 02, 2019 (GLOBE NEWSWIRE) -- Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (OTCQB: CURR) to exclusively market and...